Every one of those 1 sits in a single category, pharma. GC Biopharma is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. MAV/06 appears in 1 tracked Biotech story from March 11, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about MAV/06
Every one of those 1 sits in a single category, pharma. GC Biopharma is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. MAV/06 appears in 1 tracked Biotech story from March 11, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering MAV/06. Shared-story counts are live from our verified record — not editorial picks.
GC Biopharma has published a comprehensive review paper detailing three decades of clinical and real-world data for its proprietary MAV/06 varicella vaccine strain. This publication underscores the long-term safety and efficacy of the strain, which has been a cornerstone of the company's global vaccine portfolio and international procurement strategy.
MAV/06 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.